Michael A. Dyer, MD is an Assistant Professor of Radiation Oncology at the Boston University School of Medicine and its affiliate Boston Medical Center. He received his AB in Comparative Literature from Brown University (2005) and his MD from Harvard Medical School (2012). He completed an internship in Internal Medicine at Beth Israel Deaconess Medical Center (2013), and a residency in Radiation Oncology at the Harvard Radiation Oncology Program (2017), with training at Massachusetts General Hospital, Dana-Farber/Brigham and Women’s Cancer Center, Beth Israel Deaconess Medical Center, Boston Children’s Hospital, and Boston Medical Center. Dr. Dyer is board certified in Radiation Oncology by the American Board of Radiology. His clinical specialties include treatment of genitourinary, gynecologic, cutaneous, central nervous system, and head and neck malignancies, as well as the use of intensity-modulated radiation therapy, stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) (including Cyberknife®), and brachytherapy. His research interests include decision analysis, patient-reported outcomes and quality of life research, and clinical trials.
- Harvard Medical School, MD
- Brown University, AB
- Published on 4/1/2019
Yan SX, Qureshi MM, Dyer M, Truong MT, Mak KS. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer. Lung Cancer. 2019 May; 131:147-153. PMID: 31027693.
- Published on 1/9/2019
Shah NK, Qureshi MM, Dyer MA, Patel SA, Kim K, Everett PC, Grillone GA, Jalisi SM, Truong MT. Optimal sequencing of chemoradiotherapy for locally advanced laryngeal cancer. Laryngoscope. 2019 Jan 09. PMID: 30628077.
- Published on 9/1/2018
Burger EA, Dyer MA, Sy S, Palefsky JM, de Pokomandy A, Coutlee F, Silverberg MJ, Kim JJ. Development and Calibration of a Mathematical Model of Anal Carcinogenesis for High-Risk HIV-Infected Men. J Acquir Immune Defic Syndr. 2018 Sep 01; 79(1):10-19. PMID: 29757775.
- Published on 7/24/2018
Yan SX, Qureshi MM, Suzuki K, Dyer M, Truong MT, Litle V, Mak KS. Definitive treatment patterns and survival in stage II non-small cell lung cancer. Lung Cancer. 2018 10; 124:135-142. PMID: 30268452.
- Published on 1/1/2016
Dyer MA, Chen M, Braccioforte MH, Moran BJ, D’Amico AV. Journal of Radiation Oncology. Comorbidity and androgen deprivation therapy use in men undergoing high-dose radiation for unfavorable-risk prostate cancer. Springer Publishing. New York. 2016.
- Published on 12/15/2015
Schoenfeld JD, Mahadevan A, Floyd SR, Dyer MA, Catalano PJ, Alexander BM, McDermott DF, Kaplan ID. Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer. 2015; 3:50. PMID: 26672895.
- Published on 6/22/2014
Dyer MA, Arvold ND, Chen YH, Pinnell NE, Mitin T, Lee EQ, Hodi FS, Ibrahim N, Weiss SE, Kelly PJ, Floyd SR, Mahadevan A, Alexander BM. The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat Oncol. 2014 Jun 22; 9:143. PMID: 24954062.
- Published on 1/1/2013
Cather C, Dyer MA, Burrell HA, Hoeppner B, Goff DC, Evins AE. An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia. J Dual Diagn. 2013; 9(1):87-93. PMID: 23750123.
- Published on 7/15/2012
Dyer MA, Kelly PJ, Chen YH, Pinnell NE, Claus EB, Lee EQ, Weiss SE, Arvold ND, Lin NU, Alexander BM. Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e479-86. PMID: 22704705.
- Published on 1/25/2010
Qureshi A, Nan H, Dyer M, Han J. Polymorphisms of FAS and FAS ligand genes and risk of skin cancer. J Dermatol Sci. 2010 Apr; 58(1):78-80. PMID: 20219325.
View 3 more publications: View full profile at BUMC